HOIPIN-8
Based on 4 publication(s) in Google Scholar
HOIPIN-8 is a potent inhibitor of linear ubiquitin chain assembly complex (LUBAC) with an IC50 of 11 nM. HOIPIN-8 is a HOIPIN-1 derivative with enhanced the potency by 255-fold in the petit-LUBAC inhibition, and 10-fold and 4-fold in the LUBAC- and TNF-α-mediated NF-κB activation, respectively than HOIPIN-1. HOIPIN-1 is a promising tool to explore the cellular functions of LUBAC.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.90%
- CAS No.: 2519537-70-1
- 화학식: C23H15F2N4NaO3
- 분자량:456.38
-
보관:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Oxygen Sensing Compound Library
HY-L045
-
Ubiquitination Compound Library
HY-L050
-
Pyroptosis Compound Library
HY-L059
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) HOIPIN-8
More
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
RT-PCR
Biological Activity
HOIPIN-8 (0-100 μM; 72 hours) has little cell toxicity on A549 cells, and exhibits an IC50 value of 100 μM[1].HOIPIN-8 (0-10 μM; 24 hours) has an inhibitory effect over 10-fold enhancement over that of HOIPIN-1 on NF-κB activation, exhibits an IC50 value of 0.42 μM in HEK293T cells[1].HOIPIN-8 (0-30 μM; NF-κB luciferase reporter is transfected into cells for 18 hours; then with 10 ng/ml TNF-α for 6 h) exhibits a 4-fold enhancements of the potency than HOIPIN-1, the IC50 value is 11.9 μM. It also effectively reduces IL-1β-induced expression of NF-κB target genes, such as ICAM1 and IL-6 as compared to HOIPIN-1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human lung carcinoma A549 cells, HEK293T cells
-
Concentration:0 μM; 1 μM; 3 μM; 10 μM; 30 μM; 100 μM
-
Incubation Time:72 hours
-
Result:Did not effect A549 cell viability.
-
Cell Line:HEK293T cells
-
Concentration:0 μM; 0.3 μM; 1 μM; 10 μM; 30 μM
-
Incubation Time:24 hours
-
Result:Had an inhibitory effect on the inflammatory cytokine-induced NF-κB activation pathway.
Chemical Information
-
CAS No. 2519537-70-1
-
Appearance Solid
-
분자량 456.38
-
화학식 C23H15F2N4NaO3
-
Color Off-white to light yellow
-
SMILES
O=C(O[Na])C1=CC=C(C2=CN(C)N=C2)C=C1/C=C/C(C3=C(F)C=C(C4=CNN=C4)C=C3F)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Dev Cell
KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31. [Abstract]2025 Jun 23;60(12):1768-1783.e5. PMID: 39952242 -
J Thorac Dis
2026 Jan 31;18(1):28. PMID: 41660443 -
HOIPIN-8 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Nov 18.
THP-1 cells were pretreated with 30 µM HOIPIN-1 or HOIPIN-8 and then subjected to immunoblotting analysis.
-
HOIPIN-8 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Oct 6.
Before treatment with LLOMe (500 µM) for 2 hours, MZ-54 NHT and OTULIN KO GBM cells were pretreated with HOIPIN-8 (30 µM) for 1 hour, followed by M1 poly-Ub and NEMO staining.
HOIPIN-8 purchased from MedChemExpress. Usage Cited in: bioRxiv. 2023 Oct 6.
MZ-54 NHT and OTULIN KO GBM cells were pretreated with HOIPIN-8 (30 µM) and TPCA-1 (5 µM) for 1 hour, and then treated with LLOMe (500 µM) for 4 hours. The mRNA expression levels of IL6, IL8 and TNFA were analyzed by qRT-PCR.
용액&용해도
DMSO : 50 mg/mL (109.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (2.74 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.25 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.74 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1912 mL | 10.9558 mL | 21.9116 mL | 54.7789 mL |
| 5 mM | 0.4382 mL | 2.1912 mL | 4.3823 mL | 10.9558 mL | |
| 10 mM | 0.2191 mL | 1.0956 mL | 2.1912 mL | 5.4779 mL | |
| 15 mM | 0.1461 mL | 0.7304 mL | 1.4608 mL | 3.6519 mL | |
| 20 mM | 0.1096 mL | 0.5478 mL | 1.0956 mL | 2.7389 mL | |
| 25 mM | 0.0876 mL | 0.4382 mL | 0.8765 mL | 2.1912 mL | |
| 30 mM | 0.0730 mL | 0.3652 mL | 0.7304 mL | 1.8260 mL | |
| 40 mM | 0.0548 mL | 0.2739 mL | 0.5478 mL | 1.3695 mL | |
| 50 mM | 0.0438 mL | 0.2191 mL | 0.4382 mL | 1.0956 mL | |
| 60 mM | 0.0365 mL | 0.1826 mL | 0.3652 mL | 0.9130 mL | |
| 80 mM | 0.0274 mL | 0.1369 mL | 0.2739 mL | 0.6847 mL | |
| 100 mM | 0.0219 mL | 0.1096 mL | 0.2191 mL | 0.5478 mL |
HOIPIN-8 Related Classifications
HY-122882 Related Classifications
Powered by Bioz